You are viewing the site in preview mode
Skip to main content
|
a
|
| |
3 years [95%-CI]
|
5 years [95%-CI]
|
|
Recurrence-free survival
|
74% [67–82%]
|
72% [64–80%]
|
|
Locoregional recurrence-free survival
|
95% [91–99%]
|
92% [87–98%]
|
|
Distant metastasis-free survival
|
74% [67–82%]
|
71% [63–80%]
|
|
Cancer-specific survival
|
85% [79–92%]
|
76% [67–86%]
|
|
b
|
| |
MN/BNL
|
NPB/BNL
|
| |
3 Gy in vitro
|
End RCT (50.4Gy)
|
3 Gy in vitro
|
End RCT (50.4Gy)
|
| |
HR [CI]
|
P
|
HR [CI]
|
P
|
HR [CI]
|
P
|
HR [CI]
|
P
|
|
Recurrence-free survival
|
0.9 [0.4–1.7]
|
0.70
|
1.5 [0.7–3.0]
|
0.26
|
1.6 [0.8–3.3]
|
0.64
|
1.6 [0.8–3.3]
|
0.18
|
|
Locoregional recurrence-free survival
|
1.3 [0.3–5.6]
|
0.70
|
1.0 [0.2–3.8]
|
0.95
|
1.4 [0.4–5.8]
|
0.62
|
1.2 [0.3–4.9]]
|
0.78
|
|
Distant metastasis-free survival
|
0.6 [0.3–1.3]
|
0.21
|
1.3 [0.7–2.7]
|
0.43
|
1.3 [0.7–2.6]
|
0.46
|
1.9 [0.9–3.8]
|
0.09
|
|
Cancer-specific survival
|
0.6 [0.3–1.4]
|
0.22
|
1.3 [0.6–2.9]
|
0.57
|
1.4 [0.6–3.1]
|
0.47
|
1.9 [0.8–4.3]]
|
0.14
|
- MN micronuclei, BNL binuclear lymphocytes, NPB nucleoplasmatic bridges, RCT radiochemotherapy
